Randomized, Controlled, Double-Blind Study of Itraconazole Oral Solution Versus Fluconazole Tablets for the Treatment of Esophageal Candidiasis.
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
13 Years and older (Child, Adult, Older Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Patients must have:
Histological evidence of Candida spp. at baseline with confirmation by positive mycological culture.
HIV infection or other predisposing risk factor.
Life expectancy of at least 2 months.
Patients with the following symptoms or conditions are excluded:
Malignancies of the head or neck, if the treatment or disease will interfere with response assessment.
Evidence of systemic fungal infection.
Underlying clinical condition that would preclude study completion.
Judged to be unreliable in regard to following physician's directives.
Any investigational drug (expanded access drugs are allowed).
Patients with the following prior conditions are excluded:
History of significant hepatic abnormalities or clinical evidence of hepatic disease within 2 months prior to study entry.
History of hypersensitivity to imidazole or azole compounds.
Other orally administered antifungal therapy within 3 days prior to study entry.
Any investigational drug within 1 month prior to study entry (expanded access drugs are allowed).